MiniMed Group, Inc. MMED revenue by segment, product and geography
In its fiscal year ending 2026-04-30, MiniMed Group, Inc. reported revenue across 4 products and services; the largest, Continuous Glucose Monitoring Systems CGM, was $1.55B, 50.1% of the filed sum (+18.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Continuous Glucose Monitoring Systems CGM$1.55B50.1%+18.3% yoy
- Consumables$956M30.8%+11.9% yoy
- Pumps$546M17.6%+0.9% yoy
- Product And Service Other$46M1.5%+666.7% yoy
Members sum to the consolidated $3.1B for this period.
- Outside the United States$2.19B70.4%+20.6% yoy
- United States$917M29.6%+1.6% yoy
Members sum to the consolidated $3.1B for this period.
- Continuous Glucose Monitoring Systems CGM$390M49.4%+18.2% yoy
- Consumables$244M30.9%+14.6% yoy
- Pumps$151M19.1%+11.0% yoy
- Product And Service Other$5M0.6%-37.5% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.